In 2014, MAPS spun out a separate division to direct research and prepare for an eventual FDA software, which it submitted at the conclusion of final calendar year. In early 2024, that offshoot was renamed Lykos Therapeutics.So at the same time as blotter continues to stoke and reflect purchaser and collector desire within the 21st century, there i